CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares have had a horrible month, losing 27% after a relatively good period beforehand. The recent drop has obliterated the annual return, with the share pri
Simply Wall StApr 27 08:39 ET
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Yahoo FinanceApr 25 10:34 ET
Express News | JP Morgan Upgrades CytomX Therapeutics to Neutral
Moomoo 24/7Apr 22 08:18 ET
CytomX Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 — JP Morgan Upgrades Underweight → Neutral 03/12/2024 94.61% BMO Capital $3.3 → $3.25 Maintain
BenzingaApr 22 08:17 ET
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
TipRanksApr 22 04:20 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by
BenzingaApr 10 16:31 ET
Express News | CytomX Therapeutics Doses First Patient With CX-2051 In Phase 1 Study In Patients With Advanced Solid Tumors
Moomoo 24/7Apr 8 08:22 ET
CytomX Therapeutics Announces First Patient Dosed With CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients With Advanced Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors.
GlobeNewswireApr 8 08:00 ET
CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress
TipRanksMar 25 06:17 ET
CytomX Therapeutics Welcomes New Director and Updates Bylaws
TipRanksMar 22 16:23 ET
Press Release: CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of condi
Dow JonesMar 21 08:00 ET
CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration With Astellas
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad
GlobeNewswireMar 18 08:00 ET
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 13 06:28 ET
CytomX Therapeutics Braces for Increased Compliance Costs as It Outgrows 'Smaller Company' Status
TipRanksMar 13 02:02 ET
CytomX Falls as Bristol Myers Ends Deal for Cancer Therapy
Seeking AlphaMar 12 13:26 ET
Express News | CytomX Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. Also, BMO Capital Maintained a Market Perform Rating on the Stock and Lowered Its Price Target From $3.3 to $3.25
Moomoo 24/7Mar 12 12:50 ET
Express News | BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25
Moomoo 24/7Mar 12 11:11 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersRegulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's market cap stands at $51.5 million. Assure Hldgs (NASDAQ:IONM) stock
BenzingaMar 12 09:05 ET
Express News | Wedbush Reiterates Neutral on CytomX Therapeutics, Maintains $3 Price Target
Moomoo 24/7Mar 12 08:24 ET
Regulus RGLS Phase 1b Data; CytomX Therapeutics CTMX BMY Deal Fallout
BioPharmCatalystMar 12 07:56 ET
No Data
No Data